Four Legitimate Reasons To Prioritize Speed In Drug Therapy Development And How To Move Fast Safely

By Alex Klarer, Vice President of Business Strategy & Innovation, BioCentriq

Pharmaceutical companies are facing increased pressure to accelerate therapy development and manufacturing timelines. Pressure to meet expectations and demonstrate progress to investors, be first to market and gain market exclusivity, and address urgent, unmet medical needs make it crucial to prioritize speed. The challenge is to balance speed, cost, and quality and to prioritize speed while identifying and mitigating risks that may increase your costs in the long run.

As you consider methods for prioritizing speed as a strategic and intentional choice, partnering with a proven, transparent, and collaborative CDMO will enable you to leverage their specialized skill sets, access advanced technologies, and tap into existing infrastructure and resources. Examine considerations to help you strike the right balance to accelerate the delivery of transformative therapies while maintaining safety and upholding efficacy standards.